NEW TRENDS IN RENAL ANGIOMYOLIPOMAS THERAPY
Authors:
Tomáš Ürge 1; Tomáš Pitra 1; Zdeněk Chudáček 2; Jiří Baxa 3; Petr Stránský 1; Viktor Eret 1; Ondřej Hes 4; Milan Hora 1
Authors place of work:
Urologická klinika, Fakultní nemocnice Plzeň a LF UK v Plzni
1; Radiodiagnostické oddělení, Fakultní nemocnice Plzeň a LF UK v Plzni
2; Klinika zobrazovacích metod, Fakultní nemocnice Plzeň a LF UK v Plzni
3; Šiklův ústav patologie, Fakultní nemocnice Plzeň a LF UK v Plzni
4
Published in the journal:
Ces Urol 2015; 19(2): 106-117
Category:
Review article
Summary
Renal angiomyolipoma (AML) is a benign mesenchymal tumor, which occurs sporadically or is associated with tuberous sclerosis complex (TSC). The overall prevalence of AML is 0.44 %, its incidence in women is 4 times higher than in men. Prevalence in the female population is thus 0.6 %, but male rates 0.28 %. Diagnosis is based on the presence of fat in the tumor. In most cases AML can be identified preoperatively. AML morphology is highly variable and in cases where fat is missing, preoperative diagnostic based on imaging methods is not possible. Active monitoring of patients with AML is crucial, because AML grows slowly and with minimal morbidity. Patient can present with haematuria, pain or retroperitoneal bleeding by tumors rupture. The main risk factors for bleeding are tumors volume, percentage of the vascular component in the tumor and the presence of TSC. Selective arterial embolization resolves hemorrhagic complications and reduces the volume of the tumor. The long-term outcomes of embolisation are poor due to tumor revascularization and growth. Nephron sparring surgery is associated with better long term outcomes. Radiofrequency ablation is another option, but strongly restricted by the volume tumor. An additional option is cryoablation, which has better results in cases where tumor is large, but this requires special equipment. Systematic treatment using mTOR inhibitors (everolimus, sirolimus), has recently been introduced, which are essential in patients with TSC, where the disease is often complicated by multiple and recurrent lesion. This therapy can help reduce the total volume of AML and allow eventual resection.
Key words:
Angiomyolipoma, arterial embolization, radiofrequeci ablation, cryoablation, resection, mTOR inhibitors.
Zdroje
1. Fittschen A, Wendlik I, Oeztuerk S, et al. Prevalence of sporadic renal angiomyolipoma: a retrospective analysis of 61,389 in- and out-patients. 1. Abdom Imaging. 2014 Oct; 39 (5): 1009–1013.
2. Ürge T, Hora M, Hes O, Chudáček Z. Renální angiomyolipom, histologie, diagnostika a terapie. Čas. Lék. čes 2005; 144 (12): 821–823.
3. Nese N, Martignoni G, Fletcher CD, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: a clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol 2011, 35: 161–176
4. He W, Cheville JC, Sadow PM, et al. Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumors.Mod Pathol. 2013 Oct; 26(10): 1355–1364.
5. Hora M, Ürge T, Kalusová K, Michal M, et al. Novelizovaná klasifikace nádorů ledvin 2013 (International society of urological pathology Vancouver classification of renal neoplasia). Ces Urol 2014; 18(1): 9–20.
6. Zedebin D, Kammerhober F, Uggowitzer MM, Szolar DH. Criteria for ultrasound differentiation of small angiomyolipomas ( < 3cm) and renal cell carcinomas. RoFo Forschr Geb Rontgenster Neuen Bilgeb Verfahr 1998; 169: 627–632.
7. Tanaka H, Yoshida S, Fujii Y, et al. Diffusion-weighted magnetic resonance imaging in the differentiation of angiomyolipoma with minimal fat from clear cell renal cell carcinoma. Int J Urol. 2011 Oct; 18 (10): 727–308.
8. Halpenny D, Snow A, McNeill G, Torreggiani WC. The radiological diagnosis and treatment of renal angiomyolipoma – current status. Clinical Radiology 2010; 65: 99–108.
9. Mues AC, Palacios JM, Haramis G, et al. Contemporary experience in the management of angiomyolipoma. J Endourol 2010 Nov; 24(11): 1883–1886.
10. Eble JN, Sauter G, Epstein JI, et al. (eds). Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. Lyon: IARC Press, 2004: 9–87.
11. Oesterling JE, Fishman EK, Goldman SM, Marshall FF. The management of renal angiomyolipoma. J Urol 1986; 135: 1121–1124.
12. Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. J Urol 2002. Oct; 168 (4 Pt 1): 1315–1325.
13. Sooriakumaran P, Gibbs P, Coughlin G, et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int. 2010; 105(1): 101–106.
14. Ouzaid I, Autorino R, Fatica R, et al. Active surveillance for renal angiomyolipoma: outcomes and factors predictive of delayed intervention. BJU Int. 2014 Sep; 114 (3): 412–417.
15. Sýkora R, Fabišovský M, Němec D, Vašík J, Krhut J. Život ohrožující krvácení do dutiny břišní na podkladě spontánní ruptury angiomyolipomu. Ces Urol 2013; 17(1): 51–54.
16. Dickinson M, Ruckle H, Beaghler M, Hadley HR. Renal angiomyolipoma: optimal treatment based on size and symptoms. Clin Nephrol. 1998; 49(5): 281–286.
17. Yamakado K, Tanaka N, Nakawaga T, et al. Renal angiomyolipoma: relationships between tumour size, aneurysm formation and ruptute. Radiology 2002; 225: 78–82.
18. Han YM, Kim JK, Roh BS, et al. Renal angiomyolipoma: selective arterial embolization-effectiveness and changes in angiomyogenic components in long-term follow-up. Radiology. 1997; 204(1): 65–70.
19. Ramon J, Rimon U, Garniek A, et al. Renal angiomyolipoma: long-term results following selective arterial embolization. Eur Urol 2009 May; 55(5): 1155–1161.
19. Kothary N, McClarc S, Clark TW, et al. Ranal angiomyolipoma: long term results after arterial embolization. J Vasc Interv Radiol 2005; 16(1): 45–50.
20. Ewalt DH, Diamond N, Rees C, et al. Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex. J Urol. 2005; 174(5): 1764–1766.
21. Chi Kwok Chan, Simon Yu, Sidney Yip, and Paul Lee. The efficacy, safety and durability of selective renal arterial embolization in treating symptomatic and asymptomatic renal angiomyolipoma. UROLOGY 2011; 77(3): 641–648.
22. Stránský P, Chudáček Z, Havel V, et al. Možnosti intervenční radiologie při léčbě nádorů ledvin. Ces Urol 2012; 16(1): 50–57.
23. Bishay VL, Crino PB, Wein AJ, et al. Embolization of giant renal angiomyolipomas: technique and results. J Vasc Interv Radiol. 2010; 21(1): 67–72.
24. Hocquelet A, Cornelis F, Le Bras Y, et al. Long-term results of preventive embolization of renal angiomyolipomas: evaluation of predictive factors of volume decrease. Eur Radiol. 2014 Aug; 24(8): 1785–1793.
25. Prevoo W, van den Bosch MA, Horenblas S. Radiofrequency ablation for treatment of sporadic angiomyolipoma. Urology. 2008; 72(1): 188–191.
26. Castle SM, Gorbatiy V, Ekwenna O, Young E, Leveillee RJ. Radiofrequency ablation (RFA) therapy for renal angiomyolipoma (AML): an alternative to angio-embolization and nephron-sparing surgery. BJU Int. 2012; 109(3): 384–387.
27. Morávek P jr, Morávek P, Dvořák P. Perkutánní radiofrekvenční ablace (RFA) v léčbě nádorů ledvin – vlastní zkušenosti. Ces Urol 2010; 14(2): 104–109.
28. Jacomides L, Ogan K, Watumull L, Cadeddu JA. Laparoscopic application of radio frequency energy enables in situ renal tumor ablation and partial nephrectomy. J Urol. 2003; 169(1): 49–53.
29. Davenport MS, Cavili EM, Cohan RH, et al. MRI and CT characteristics of success fully ablated renal masses: Imaging surveillance after radiofrequency ablation. ARJ AM J Roentgenol 2009; 192(6): 1571–1578.
30. Klingler HC, Marberger M, Mauermann J, et al. ‘Skipping’ is still a problem with radiofrequency ablation of small renal tumours. BJU Int 2007; 99: 998–1001.
31. Delworth MG, Pisters LL, Fornage BD, von Eschenbach AC. Cryotherapy for renal cell carcinoma and angiomyolipoma. J Urol. 1996; 155(1): 252–254.
32. Johnson SC, Graham S, D’Agostino H, Elmajian DA, Shingleton WB. Percutaneous renal cryoablation of angiomyolipomas in patients with solitary kidneys. Urology. 2009; 74(6): 1246–1249.
33. Byrd GF, Lawatsch EJ, Mesrobian HG, Begun F, Langenstroer P. Laparoscopic cryoablation of renal angiomyolipoma. J Urol. 2006; 176 (4 Pt 1): 1512–1516.
34. Weight CJ, Kaouk JH, Hegarty NJ, et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol 2008; 179(4): 1277–1281.
35. Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma – a meta-analysis and review. J Urol 2008; 179 (4): 1227–1233.
36. Boorjian SA, Frank I, Inman B, Lohse Ch M, Cheville JC, et al. The Role of Partial Nephrectomy for the Management of Sporadic Renal Angiomyolipoma. UROLOGY 2007; 70: 1064–1068.
37. Heidenreich A, Hegele A, Varga Z, vonKnobloch R, Hofmann R. Nephron sparing surgery for renal angiomyolipoma. Eur Urol 2002; 41: 267–273.
38. Čermák A, Pacík D, Vít V. Současný pohled na léčbu malých nádorů ledvin. Urol List 2012; 10(3): 6–15.
39. Hora M, Eret V, Ürge T, et al. Results of laparoscopic resection of kidney tumour in everyday clinical practice, CEJU (Central European Journal of Urology), 2009, 62(3): 160–166.
40. Msezane L, Chang A, Shikanov S, et al. Laparoscopic nephronsparing surgery in the management of angiomyolipoma: a single center experience. J Endourol. 2010; 24(4): 583–587.
41. Simmons MN, Chung BI, Gill IS. Perioperative efficacy of laparoscopic partial nephrectomy for tumors larger than 4 cm. Eur Urol. 2009; 55(1): 199–207.
42. Lane BR, Aydin H, Danforth TL, et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J Urol. 2008; 180(3): 836–843.
43. Schips L, Berardinelli F, Neri F, Tamburro FR, Cindolo L. Laparoendoscopic single-site partial nephrectomy without ischemia for very small, exophytic renal masses: surgical details and functional outcomes. Eur Urol. 2012.
44. Bolufer E, López-Fontana G, Castillo OA. Robot assisted partial nephrectomy (Da Vinci) in an angiomyolipoma associated to Wünderlich Syndrome. Arch Esp Urol. 2012; 65(9): 831–834.
45. El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 2003; 63(17): 5173–5177.
46. Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and. PLoS One. 2011; 6(9): e23379.
47. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. 1. Lancet. 2013 Mar 9; 381(9869): 817.
48. Staehler M, Sauter M, Helck A, et al. Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis. Int Urol Nephrol 2012 Dec; 44 (6): 1657–1661.
Štítky
Paediatric urologist Nephrology UrologyČlánok vyšiel v časopise
Czech Urology
2015 Číslo 2
Najčítanejšie v tomto čísle
- NEW TRENDS IN RENAL ANGIOMYOLIPOMAS THERAPY
- LIPOSARCOMA AND GANGLIONEUROMA AS PRIMARY RETROPERITONEAL TUMOURS
- TUMOR GLANS AS A CLINICAL MANIFESTATION OF PLASMABLASTIC LYMPHOMA
- PHYSIOTHERAPY IN TREATING URINARY INCONTINENCE IN WOMEN